Trial Profile
A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY, CLINICAL ACTIVITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB (MSB0010718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Ivuxolimab (Primary) ; NKTR 255 (Primary) ; PD 360324 (Primary) ; Utomilumab (Primary)
- Indications Advanced breast cancer; Bladder cancer; Cervical cancer; Endometrial cancer; Gastric cancer; Giant cell tumour of tendon sheath; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms JAVELIN Bladder Medley; JAVELIN Medley
- Sponsors Pfizer
- 12 Oct 2023 Results (n=40) assessing safety and efficacy of avelumab combined with utomilumab and PF-04518600 in patients with recurrent gynecologic malignancies, published in the Cancer.
- 04 Jun 2023 This trial has been completed in Netherlands, according to European Clinical Trials Database record.
- 04 May 2023 Status changed from active, no longer recruiting to discontinued. The study was terminated since there was no need for further safety or efficacy data to becollected. The participants having benefit from investigational treatments have been movedto a continuation study (NCT05059522)